View Future GrowthBioter 過去の業績過去 基準チェック /06Bioterの収益は年間平均-29.6%の割合で減少していますが、 Construction業界の収益は年間 増加しています。収益は年間44% 29.6%割合で 増加しています。主要情報-29.64%収益成長率-29.63%EPS成長率Construction 業界の成長41.75%収益成長率29.57%株主資本利益率n/aネット・マージン-1,693.86%前回の決算情報31 Dec 2024最近の業績更新Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.すべての更新を表示Recent updatesReported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceNew Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens GreeceBoard Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United KingdomIs New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.収支内訳Bioter の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史ATSE:BIOT 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 241-2113030 Sep 241-177030 Jun 240-121031 Mar 240-122031 Dec 230-122030 Sep 230-113030 Jun 230-93031 Mar 230-102031 Dec 220-101030 Sep 220-101030 Jun 220-101031 Mar 220-101031 Dec 210-91030 Sep 21001030 Jun 21081031 Mar 21071031 Dec 20061030 Sep 200-21030 Jun 200-111031 Mar 200-101031 Dec 190-91030 Sep 190-111030 Jun 190-131031 Mar 190-131031 Dec 180-131030 Sep 180-151030 Jun 180-181031 Mar 180-181031 Dec 170-181030 Sep 170-181030 Jun 171-181031 Mar 171-181031 Dec 161-181030 Sep 160-161030 Jun 160-101031 Mar 160-101031 Dec 151-101030 Sep 153-142030 Jun 154-142031 Mar 155-122031 Dec 145-142030 Sep 144-1120質の高い収益: BIOTは現在利益が出ていません。利益率の向上: BIOTは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BIOTは利益が出ておらず、過去 5 年間で損失は年間29.6%の割合で増加しています。成長の加速: BIOTの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: BIOTは利益が出ていないため、過去 1 年間の収益成長をConstruction業界 ( 160.7% ) と比較することは困難です。株主資本利益率高いROE: BIOTの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCapital-goods 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/27 16:59終値2025/05/30 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioter S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.
Reported Earnings • May 05Full year 2024 earnings released: €1.27 loss per share (vs €0.70 loss in FY 2023)Full year 2024 results: €1.27 loss per share (further deteriorated from €0.70 loss in FY 2023). Net loss: €21.3m (loss widened 82% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 30Bioter S.A., Annual General Meeting, Jul 10, 2025Bioter S.A., Annual General Meeting, Jul 10, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$318k). Market cap is less than US$10m (€3.26m market cap, or US$3.70m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end).
New Risk • Oct 04New major risk - Revenue and earnings growthEarnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€11m free cash flow). Share price has been highly volatile over the past 3 months (6.6% average weekly change). Negative equity (-€124m). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m (€280k revenue, or US$309k). Market cap is less than US$10m (€4.52m market cap, or US$4.98m).
お知らせ • Apr 28Bioter S.A. to Report Fiscal Year 2023 Results on Apr 29, 2024Bioter S.A. announced that they will report fiscal year 2023 results on Apr 29, 2024
New Risk • Apr 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€112m). Revenue is less than US$1m (€471k revenue, or US$502k). Market cap is less than US$10m (€4.58m market cap, or US$4.88m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
お知らせ • Jul 01Bioter S.A., Annual General Meeting, Jul 21, 2023Bioter S.A., Annual General Meeting, Jul 21, 2023, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
New Risk • Jul 01New major risk - Revenue and earnings growthRevenue has declined by 17% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€102m). Revenue has declined by 17% over the past year. Revenue is less than US$1m (€241k revenue, or US$263k). Market cap is less than US$10m (€3.51m market cap, or US$3.83m). Minor Risk Latest financial reports are more than 6 months old (reported June 2022 fiscal period end).
Reported Earnings • Oct 04First half 2022 earnings released: €0.30 loss per share (vs €0.22 loss in 1H 2021)First half 2022 results: €0.30 loss per share (further deteriorated from €0.22 loss in 1H 2021). Net loss: €5.10m (loss widened 38% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 01Bioter S.A., Annual General Meeting, Sep 05, 2022Bioter S.A., Annual General Meeting, Sep 05, 2022, at 09:00 E. Europe Standard Time. Location: 45 Eftichidou str Athens Greece
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • May 06Robust Earnings May Not Tell The Whole Story For Bioter (ATH:BIOT)Bioter S.A.'s ( ATH:BIOT ) robust recent earnings didn't do much to move the stock. We believe that shareholders have...
Is New 90 Day High Low • Jan 04New 90-day high: €0.38The company is up 348% from its price of €0.084 on 06 October 2020. The Greek market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 22% over the same period.
お知らせ • Jan 02Bioter S.A., Annual General Meeting, Jan 11, 2021Bioter S.A., Annual General Meeting, Jan 11, 2021, at 11:00 E. Europe Standard Time. Location: 45 Eftichidou str. Athens United Kingdom
Is New 90 Day High Low • Dec 16New 90-day high: €0.22The company is up 154% from its price of €0.085 on 17 September 2020. The Greek market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Construction industry, which is up 13% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total losses of €12.3m, with losses narrowing by 5.0% from the prior year.